Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


11.04.2022

1 Adv Radiat Oncol
1 Adv Sci (Weinh)
8 Aktuelle Urol
1 Ann R Coll Surg Engl
1 Appl Immunohistochem Mol Morphol
1 Asian J Endosc Surg
1 Biochem Cell Biol
1 BJU Int
1 BMC Cancer
1 BMC Med Genomics
1 BMC Nephrol
1 BMC Urol
1 BMJ Case Rep
1 BMJ Open
1 Bosn J Basic Med Sci
1 Can J Urol
1 Cancer Biomark
1 Cancer Discov
1 Cancer Res
2 Cell Death Dis
1 Cells
1 Chemotherapy
1 Clin Radiol
1 Cochrane Database Syst Rev
1 Comput Math Methods Med
1 Cureus
3 Diagn Cytopathol
1 Dis Markers
1 Einstein (Sao Paulo)
1 Eur J Med Chem
1 Eur J Radiol
1 Eur Urol
1 Front Cell Dev Biol
2 Front Immunol
1 Hum Pathol
1 Indian J Tuberc
2 Int Braz J Urol
2 Int J Mol Sci
4 Int J Urol
1 J Am Heart Assoc
1 J Am Soc Cytopathol
2 J Cancer Res Ther
1 J Healthc Eng
1 J Pathol Clin Res
1 J Transl Med
1 J Urol
2 JCO Precis Oncol
1 Med Phys
1 Mol Cancer Res
1 Mol Cancer Ther
1 Mol Oncol
3 Nat Commun
2 Nat Rev Urol
1 Onco Targets Ther
1 Oxid Med Cell Longev
1 Pathol Oncol Res
1 Photodiagnosis Photodyn Ther
2 Rozhl Chir
1 Scand J Urol
1 Sci Rep
2 Urol Oncol
1 Urologe A
3 Virchows Arch


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Adv Radiat Oncol

  1. GREER MD, Schaub SK, Bowen SR, Liao JJ, et al
    A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy.
    Adv Radiat Oncol. 2021;7:100858.
    PubMed         Abstract available


    Adv Sci (Weinh)

  2. SUN B, Bte Rahmat JN, Kim HJ, Mahendran R, et al
    Wirelessly Activated Nanotherapeutics for In Vivo Programmable Photodynamic-Chemotherapy of Orthotopic Bladder Cancer.
    Adv Sci (Weinh). 2022 Apr 7:e2200731. doi: 10.1002/advs.202200731.
    PubMed         Abstract available


    Aktuelle Urol



  3. Aktuelle Urol. 2022;53:119-121.
    PubMed        

  4. BOLENZ C, Ohlmann CH, Gschwend J
    [Do's and Dont's for radical cystectomy and urinary diversion - how to minimise postoperative complications].
    Aktuelle Urol. 2022;53:159-166.
    PubMed         Abstract available

  5. NIEGISCH G

    Aktuelle Urol. 2022;53:135-136.
    PubMed        



  6. Aktuelle Urol. 2022;53:110-112.
    PubMed        



  7. Aktuelle Urol. 2022;53:112-114.
    PubMed        



  8. Aktuelle Urol. 2022;53:114-116.
    PubMed        



  9. Aktuelle Urol. 2022;53:116.
    PubMed        

  10. TAUBER R, von Amsberg G, De Santis M
    [Update on systemic treatment of urothelial cancer: therapy in transition].
    Aktuelle Urol. 2022;53:167-179.
    PubMed         Abstract available


    Ann R Coll Surg Engl

  11. O'CONNOR A, Sabri S, Muhammad K
    The use of methylene blue to aid identification of ileal conduit anatomy during subsequent surgery.
    Ann R Coll Surg Engl. 2022;104:1.
    PubMed        


    Appl Immunohistochem Mol Morphol

  12. KE HL, Lee YC, Li WM, Wang CS, et al
    High Ubiquitin-Specific Protease 2a Expression Level Predicts Poor Prognosis in Upper Tract Urothelial Carcinoma.
    Appl Immunohistochem Mol Morphol. 2022;30:304-310.
    PubMed         Abstract available


    Asian J Endosc Surg

  13. KAMEI J, Fujisaki A, Saito K, Sugihara T, et al
    Less invasive and equivalent short-term outcomes with simultaneous en bloc robot-assisted radical cystectomy and laparoscopic nephroureterectomy: Comparison with conventional open radical cystectomy and nephroureterectomy.
    Asian J Endosc Surg. 2022;15:255-260.
    PubMed         Abstract available


    Biochem Cell Biol

  14. SHANG D, Li G, Zhang C, Liu Y, et al
    Synergistic inhibitory effects of 5-aza-2'-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways.
    Biochem Cell Biol. 2022;100:115-124.
    PubMed         Abstract available


    BJU Int

  15. ALMASSI N, Vertosick EA, Sjoberg DD, Wong NC, et al
    Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy.
    BJU Int. 2022;129:463-469.
    PubMed         Abstract available


    BMC Cancer

  16. FANG C, Huang X, Dai J, He W, et al
    The circular RNA circFARSA sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
    BMC Cancer. 2022;22:373.
    PubMed         Abstract available


    BMC Med Genomics

  17. ZHANG H, Lu X, Huang G, Hua M, et al
    A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
    BMC Med Genomics. 2022;15:1.
    PubMed         Abstract available


    BMC Nephrol

  18. YANISHI M, Kinoshita H
    Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury.
    BMC Nephrol. 2022;23:125.
    PubMed         Abstract available


    BMC Urol

  19. YAMASAKI M, Taoka R, Katakura K, Matsunaga T, et al
    The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma.
    BMC Urol. 2022;22:51.
    PubMed         Abstract available


    BMJ Case Rep

  20. HAROLD JA, Casilla-Lennon M, Kenney PA, Ratner ES, et al
    Vesical clear cell adenocarcinoma of Mullerian origin treated conservatively with partial cystectomy.
    BMJ Case Rep. 2022;15.
    PubMed         Abstract available


    BMJ Open

  21. PATTENDEN T, Samaranayake D, Morton A, Thangasamy I, et al
    Bladder cancer in Aboriginal and Torres Strait Islander people living in Australia: a scoping review protocol.
    BMJ Open. 2022;12:e059144.
    PubMed         Abstract available


    Bosn J Basic Med Sci

  22. GAO X, Lin B, Lin Q, Ye T, et al
    A HALP score-based prediction model for survival of patients with the upper tract urothelial carcinoma undergoing radical nephroureterectomy.
    Bosn J Basic Med Sci. 2022;22:280-290.
    PubMed         Abstract available


    Can J Urol

  23. ALGER J, Mallahan C, Deng T, Marshall J, et al
    Neuroendocrine tumor causing ureteral obstruction in a patient with prior ileal conduit.
    Can J Urol. 2021;28:10953-10955.
    PubMed         Abstract available


    Cancer Biomark

  24. MURAKAMI K, Kamat AM, Dai Y, Pagano I, et al
    Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study.
    Cancer Biomark. 2022;33:151-157.
    PubMed         Abstract available


    Cancer Discov


  25. Bicyclic Peptide Makes Targeting EphA2 Possible.
    Cancer Discov. 2021;11:2951-2952.
    PubMed         Abstract available


    Cancer Res

  26. AN M, Zheng H, Huang J, Lin Y, et al
    Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer.
    Cancer Res. 2022 Apr 8. pii: 694333. doi: 10.1158/0008-5472.CAN-21-4349.
    PubMed         Abstract available


    Cell Death Dis

  27. YANG J, Qi M, Fei X, Wang X, et al
    Hsa_circRNA_0088036 acts as a ceRNA to promote bladder cancer progression by sponging miR-140-3p.
    Cell Death Dis. 2022;13:322.
    PubMed         Abstract available

  28. DENG M, Wang N, Li Z, Chen R, et al
    FXR1 can bind with the CFIm25/CFIm68 complex and promote the progression of urothelial carcinoma of the bladder by stabilizing TRAF1 mRNA.
    Cell Death Dis. 2022;13:170.
    PubMed         Abstract available


    Cells

  29. CHAN TC, Hsing CH, Shiue YL, Huang SK, et al
    Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression.
    Cells. 2022;11.
    PubMed         Abstract available


    Chemotherapy

  30. MAEYAMA R, Ikeda M, Shimura S, Amano N, et al
    Patients with Non-Muscle Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guerin Intravesical Instillation Therapy.
    Chemotherapy. 2022 Apr 7. pii: 000524449. doi: 10.1159/000524449.
    PubMed         Abstract available


    Clin Radiol

  31. CUI Y, Sun Z, Liu X, Zhang X, et al
    CT-based radiomics for the preoperative prediction of the muscle-invasive status of bladder cancer and comparison to radiologists' assessment.
    Clin Radiol. 2022 Mar 30. pii: S0009-9260(22)00130.
    PubMed         Abstract available


    Cochrane Database Syst Rev

  32. LAI LY, Tafuri SM, Ginier EC, Herrel LA, et al
    Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer.
    Cochrane Database Syst Rev. 2022;4:CD014887.
    PubMed         Abstract available


    Comput Math Methods Med

  33. SHAO C, Sun A, Xue H, Di X, et al
    Three-Dimensional Ultrasound Images in the Assessment of Bladder Tumor Health Monitoring under Deep Learning Algorithms.
    Comput Math Methods Med. 2022;2022:9170274.
    PubMed         Abstract available


    Cureus

  34. ADNAN S, Abu Bakar M, Khalil MAI, Fiaz S, et al
    Outcomes of Uretero-ileal Anastomosis in Bladder Cancer Cystectomies: Bricker vs. Wallace 1.
    Cureus. 2022;14:e22782.
    PubMed         Abstract available


    Diagn Cytopathol

  35. ALLISON DB, Kates M, VandenBussche CJ
    Indeterminate atypia in urinary tract cytology: Does it really matter?
    Diagn Cytopathol. 2022;50:176-183.
    PubMed         Abstract available

  36. PATEL SH
    Clinician's commentary: Atypia in urinary tract cytology specimens.
    Diagn Cytopathol. 2022;50:184-185.
    PubMed         Abstract available

  37. KOBAYASHI G, Uraoka N, Sentani K, Shibata J, et al
    Cytological and histological findings of upper tract mucinous urothelial carcinoma with clear cell component: A case report and review of literature.
    Diagn Cytopathol. 2022;50:E129-E135.
    PubMed         Abstract available


    Dis Markers

  38. LI Z, Wang S, Chen Y, Huang Y, et al
    5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer.
    Dis Markers. 2022;2022:3117359.
    PubMed         Abstract available


    Einstein (Sao Paulo)

  39. MONTEIRO CRA, Korkes F, Krutman-Zveibil D, Glina S, et al
    Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence.
    Einstein (Sao Paulo). 2022;20:eAO6450.
    PubMed         Abstract available


    Eur J Med Chem

  40. LU D, Yang T, Tang N, Li C, et al
    A pH-Dependent rhodamine fluorophore with antiproliferative activity of bladder cancer in Vitro/Vivo and apoptosis mechanism.
    Eur J Med Chem. 2022;236:114293.
    PubMed         Abstract available


    Eur J Radiol

  41. ELSHETRY ASF, El-Fawakry RM, Hamed EM, Metwally MI, et al
    Diagnostic accuracy and discriminative power of biparametric versus multiparametric MRI in predicting muscle-invasive bladder cancer.
    Eur J Radiol. 2022;151:110282.
    PubMed         Abstract available


    Eur Urol

  42. ERTL IE, Lemberger U, Ilijazi D, Hassler MR, et al
    Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.
    Eur Urol. 2022 Apr 4. pii: S0302-2838(22)01678.
    PubMed         Abstract available


    Front Cell Dev Biol

  43. XIA QD, Sun JX, Liu CQ, Xu JZ, et al
    Ferroptosis Patterns and Tumor Microenvironment Infiltration Characterization in Bladder Cancer.
    Front Cell Dev Biol. 2022;10:832892.
    PubMed         Abstract available


    Front Immunol

  44. XIONG Q, Feng D, Wang Z, Ying Y, et al
    Fatty Acid Synthase Is the Key Regulator of Fatty Acid Metabolism and Is Related to Immunotherapy in Bladder Cancer.
    Front Immunol. 2022;13:836939.
    PubMed         Abstract available

  45. YANG M, Wang B, Hou W, Yu H, et al
    Negative Effects of Stromal Neutrophils on T Cells Reduce Survival in Resectable Urothelial Carcinoma of the Bladder.
    Front Immunol. 2022;13:827457.
    PubMed         Abstract available


    Hum Pathol

  46. BERNARDO C, Eriksson P, Marzouka NA, Liedberg F, et al
    Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours: An integrated immunohistochemical analysis.
    Hum Pathol. 2022;122:11-24.
    PubMed         Abstract available


    Indian J Tuberc

  47. TALWAR HS, Kumar S, Mittal A, Narain TA, et al
    Incidental encounter of intraperitoneal tuberculosis during renal surgeries: A surgeon's dilemma.
    Indian J Tuberc. 2022;69:246-249.
    PubMed         Abstract available


    Int Braz J Urol

  48. SHARMA G, Yadav AK, Pareek T, Kaundal P, et al
    Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis.
    Int Braz J Urol. 2022;48:406-455.
    PubMed         Abstract available

  49. FAVORITO LA
    Upper tract urothelial carcinoma and bladder cancer in review in this number of International Brazilian Journal of Urology.
    Int Braz J Urol. 2022;48:386-388.
    PubMed        


    Int J Mol Sci

  50. CASARIN M, Fortunato TM, Imran S, Todesco M, et al
    Porcine Small Intestinal Submucosa (SIS) as a Suitable Scaffold for the Creation of a Tissue-Engineered Urinary Conduit: Decellularization, Biomechanical and Biocompatibility Characterization Using New Approaches.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  51. CINQUE A, Capasso A, Vago R, Floris M, et al
    MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available


    Int J Urol

  52. OZAKI K, Hatakeyama S, Hamaya T, Okita K, et al
    Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
    Int J Urol. 2022;29:362-364.
    PubMed        

  53. MIYAKE M
    Editorial Comment to Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma.
    Int J Urol. 2022;29:364-365.
    PubMed        

  54. TELLINI R, Mari A, Minervini A
    Editorial Comment from Dr Tellini et al. to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14895.
    PubMed        

  55. HAYAKAWA N, Kikuchi E
    Editorial Comment from Dr Hayakawa and Dr Kikuchi to Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).
    Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14888.
    PubMed        


    J Am Heart Assoc

  56. LIU E, Guan X, Wei R, Jiang Z, et al
    Association Between Radiotherapy and Death From Cardiovascular Disease Among Patients With Cancer: A Large Population-Based Cohort Study.
    J Am Heart Assoc. 2022;11:e023802.
    PubMed         Abstract available


    J Am Soc Cytopathol

  57. WOJCIK EM, Kurtycz DFI, Rosenthal DL
    We'll always have Paris The Paris System for Reporting Urinary Cytology 2022.
    J Am Soc Cytopathol. 2022;11:62-66.
    PubMed         Abstract available


    J Cancer Res Ther

  58. GURAL Z, Yucel S, Oskeroglu S, Agaoglu F, et al
    Urachal adenocarcinoma: A case report and review of the literature.
    J Cancer Res Ther. 2022;18:291-293.
    PubMed         Abstract available

  59. LI K, Wang F, Wang J, Fan C, et al
    Marital status independently predicts survival of patients with upper urinary tract urothelial carcinoma: A population-based study.
    J Cancer Res Ther. 2021;17:1709-1717.
    PubMed         Abstract available


    J Healthc Eng

  60. YANG X, Lv H, Jiang W, Zhang J, et al
    Clinical Value Analysis of Xiaozheng Decoction Combined with Bladder Perfusion for Postoperative Treatment of Bladder Cancer and Its Effect on Serum miR-143 and miR-92a.
    J Healthc Eng. 2022;2022:8177674.
    PubMed         Abstract available


    J Pathol Clin Res

  61. HURST CD, Cheng G, Platt FM, Alder O, et al
    Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling.
    J Pathol Clin Res. 2022;8:279-293.
    PubMed         Abstract available


    J Transl Med

  62. LIU L, Qiu M, Tan G, Liang Z, et al
    Correction to: miR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3.
    J Transl Med. 2022;20:153.
    PubMed        


    J Urol


  63. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.
    J Urol. 2022;207:1166.
    PubMed        


    JCO Precis Oncol

  64. YIN Y, Song L, Shi D, Liu B, et al
    Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.
    JCO Precis Oncol. 2022;6:e2100325.
    PubMed         Abstract available

  65. ZABOR EC, Kaizer AM, Garrett-Mayer E, Hobbs BP, et al
    Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts.
    JCO Precis Oncol. 2022;6:e2100390.
    PubMed         Abstract available


    Med Phys

  66. YU J, Cai L, Chen C, Fu X, et al
    Cascade Path Augmentation Unet for Bladder Cancer Segmentation in MRI.
    Med Phys. 2022 Apr 7. doi: 10.1002/mp.15646.
    PubMed         Abstract available


    Mol Cancer Res

  67. XIAO JF, Kua LF, Ding LW, Sun QY, et al
    KDM6A Depletion in Breast Epithelial Cells Leads to Reduced Sensitivity to Anticancer Agents and Increased TGFbeta Activity.
    Mol Cancer Res. 2022;20:637-649.
    PubMed         Abstract available


    Mol Cancer Ther

  68. BOULEFTOUR W, Guillot A, Magne N
    The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
    Mol Cancer Ther. 2022;21:493-501.
    PubMed         Abstract available


    Mol Oncol

  69. LUNA-VELEZ MV, Dijkstra JJ, Heuschkel MA, Smit FP, et al
    Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder.
    Mol Oncol. 2021;15:1882-1900.
    PubMed         Abstract available


    Nat Commun

  70. ALHALABI O, Chen J, Zhang Y, Lu Y, et al
    MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
    Nat Commun. 2022;13:1797.
    PubMed         Abstract available

  71. TABER A, Christensen E, Lamy P, Nordentoft I, et al
    Author Correction: Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.
    Nat Commun. 2022;13:1916.
    PubMed        

  72. VAN DER HEIJDEN MS, Powles T, Petrylak D, de Wit R, et al
    Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.
    Nat Commun. 2022;13:1878.
    PubMed         Abstract available


    Nat Rev Urol

  73. STONE L
    Urinary VOCs as bladder cancer biomarkers.
    Nat Rev Urol. 2022 Apr 8. pii: 10.1038/s41585-022-00595.
    PubMed        

  74. THEODORESCU D, Li Z, Li X
    Sex differences in bladder cancer: emerging data and call to action.
    Nat Rev Urol. 2022 Apr 4. pii: 10.1038/s41585-022-00591.
    PubMed        


    Onco Targets Ther

  75. LI M, Che N, Jin Y, Li J, et al
    CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming.
    Onco Targets Ther. 2022;15:299-311.
    PubMed         Abstract available


    Oxid Med Cell Longev

  76. ZHAO C, Xiong K, Ji Z, Liu F, et al
    The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis.
    Oxid Med Cell Longev. 2022;2022:8297011.
    PubMed         Abstract available


    Pathol Oncol Res

  77. JIANG Y, Zhang Z, Wang X, Feng Z, et al
    A Novel Prognostic Factor TIPE2 in Bladder Cancer.
    Pathol Oncol Res. 2022;28:1610282.
    PubMed         Abstract available


    Photodiagnosis Photodyn Ther

  78. TAOKA R, Matsuoka Y, Yamasaki M, Kani N, et al
    Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2022 Apr 2:102838.
    PubMed         Abstract available


    Rozhl Chir

  79. ZEMLICKOVA B, Brisuda A
    Prognostic factors of early second transurethral resection of non-muscle invasive bladder cancer 10 years of experience of a referral center.
    Rozhl Chir. 2022;101:119-128.
    PubMed         Abstract available

  80. HORNAK J, Brisuda A, Babjuk M
    Management of BCG failure in non-muscle-invasive bladder cancer the present and the future.
    Rozhl Chir. 2022;101:108-113.
    PubMed         Abstract available


    Scand J Urol

  81. ABUHASANEIN S, Jahnson S, Aljabery F, Gardmark T, et al
    Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience.
    Scand J Urol. 2022 Apr 7:1-6. doi: 10.1080/21681805.2022.2058605.
    PubMed         Abstract available


    Sci Rep

  82. ABEDI Z, MotieGhader H, Hosseini SS, Sheikh Beig Goharrizi MA, et al
    mRNA-miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis.
    Sci Rep. 2022;12:5885.
    PubMed         Abstract available


    Urol Oncol

  83. PIAO XM, Kim YU, Byun YJ, Zheng CM, et al
    Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy.
    Urol Oncol. 2022 Apr 2. pii: S1078-1439(21)00557.
    PubMed         Abstract available

  84. MCLOUGHLIN LC, O'Halloran S, Tjong M, Ajib K, et al
    The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer.
    Urol Oncol. 2022 Apr 4. pii: S1078-1439(22)00072.
    PubMed         Abstract available


    Urologe A

  85. ZRAIK I, Krege S
    [Follow-up in superficial and metastatic bladder cancer].
    Urologe A. 2022 Apr 5. pii: 10.1007/s00120-022-01813.
    PubMed         Abstract available


    Virchows Arch

  86. VOLKEL C, De Wispelaere N, Weidemann S, Gorbokon N, et al
    Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.
    Virchows Arch. 2022;480:433-447.
    PubMed         Abstract available

  87. LOGHIN A, Nechifor-Boila A, Borda A, Nechifor-Boila IA, et al
    Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
    Virchows Arch. 2022;480:303-313.
    PubMed         Abstract available

  88. TATJANA A, Tjota MY, O'Donnell PH, Eggener SE, et al
    EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.
    Virchows Arch. 2022;480:487-492.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: